Xtant Medical Holdings, INC 10-Q quarterly reports

Xtant Medical Holdings, Inc. reported a significant decrease in revenue for the second quarter of 2026, primarily due to divestitures and the loss of license revenue, alongside a substantial operating expense write-off.

Xtant Medical Holdings reported a 37% decrease in total revenue for the first quarter of 2026 compared to the prior year, primarily due to asset divestitures and a reduction in license revenue.

Xtant Medical Holdings, Inc. reported a significant turnaround in net income and gross profit for the nine months ended September 30, 2025, driven by licensing revenue and orthobiologics sales, while progressing with a strategic asset divestiture.

Xtant Medical Holdings, Inc. reported a significant financial turnaround in Q2 2025, achieving net income and substantial revenue growth, while announcing strategic divestitures of its Coflex/CoFix and international hardware businesses.

Xtant Medical Holdings, Inc. announces an 18% increase in revenue for the first quarter of 2025, driven by growth in orthobiologics sales and new licensing revenue.

Xtant Medical Holdings, Inc. announced its third-quarter 2024 results, showing a 12% increase in revenue compared to the same period last year, driven by recent acquisitions.

Xtant Medical Holdings saw a significant 48% increase in revenue in the second quarter of 2024 compared to the same period last year, driven by recent acquisitions, but continues to operate at a loss.

Xtant Medical has amended its credit agreements, securing an additional $5 million in term loans and adjusting prepayment fees.